- Home
- DRRX vs ACXP Comparison
DRRX vs ACXP Comparison
Compare DRRX & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRRX
- ACXP
- Stock Information
- Founded
- DRRX 1998
- ACXP 2017
- Country
- DRRX United States
- ACXP United States
- Employees
- DRRX N/A
- ACXP N/A
- Industry
- DRRX Biotechnology: Pharmaceutical Preparations
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- DRRX Health Care
- ACXP Health Care
- Exchange
- DRRX Nasdaq
- ACXP Nasdaq
- Market Cap
- DRRX N/A
- ACXP 8.4M
- IPO Year
- DRRX 2000
- ACXP 2021
- Fundamental
- Price
- DRRX $0.61
- ACXP $0.47
- Analyst Decision
- DRRX Hold
- ACXP Strong Buy
- Analyst Count
- DRRX 1
- ACXP 2
- Target Price
- DRRX N/A
- ACXP $10.00
- AVG Volume (30 Days)
- DRRX 47.0K
- ACXP 18.7M
- Earning Date
- DRRX 08-12-2025
- ACXP 08-08-2025
- Dividend Yield
- DRRX N/A
- ACXP N/A
- EPS Growth
- DRRX N/A
- ACXP N/A
- EPS
- DRRX N/A
- ACXP N/A
- Revenue
- DRRX $1,856,000.00
- ACXP N/A
- Revenue This Year
- DRRX N/A
- ACXP N/A
- Revenue Next Year
- DRRX $673.00
- ACXP N/A
- P/E Ratio
- DRRX N/A
- ACXP N/A
- Revenue Growth
- DRRX 79.84
- ACXP N/A
- 52 Week Low
- DRRX $0.48
- ACXP $0.30
- 52 Week High
- DRRX $1.74
- ACXP $3.33
- Technical
- Relative Strength Index (RSI)
- DRRX 46.88
- ACXP 52.38
- Support Level
- DRRX $0.57
- ACXP $0.45
- Resistance Level
- DRRX $0.69
- ACXP $0.59
- Average True Range (ATR)
- DRRX 0.06
- ACXP 0.08
- MACD
- DRRX -0.00
- ACXP -0.01
- Stochastic Oscillator
- DRRX 48.12
- ACXP 27.06
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.